News & Updates

Administration of surfactant into the oropharynx of neonates delivered before 29 weeks of gestation falls short of reducing the rate of intubation in the first 120 hours of life, according to the results of POPART*.

In the treatment of patients with IgA nephropathy, the use of sibeprenlimab, a humanized IgG2 monoclonal antibody that binds to and neutralizes a proliferation-inducing ligand (APRIL), appears to lead to a significant reduction in proteinuria, according to a phase II trial.

The glucagon/GLP-1 receptor dual agonist survodutide appears to be safe and induce weight loss in individuals with obesity, according to data from a phase II dose-finding trial.

Treatment with the anti-influenza A virus inhibitor onradivir is safe and leads to symptom improvement and viral load reduction in adults with uncomplicated influenza infection, according to data from a phase II trial.

Treatment with erdafitinib or pembrolizumab results in similar median overall survival (OS) in pretreated patients with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor (FGFR) alterations (FGFRalt), a study has shown. Safety results are also comparable to the known profiles for both regimens in this patient population.

Among hospitalized patients treated with direct oral anticoagulants (DOACs), an elevated international normalized ratio (INR) upon admission may spell an increased risk for in-hospital death or mortality during the first year following hospitalization, suggests a study.

Babies born to mothers who were exposed to low-dose aspirin during pregnancy do not appear to have altered neurodevelopmental outcomes at age 3 years, according to a study.